SmartCella

SmartCella, founded in 2014, is a world-leading biotechnology company that pioneers the future of targeted therapies by combining novel delivery platforms, such as the FDA-approved Extroducer (an intravascular device capable of direct infusion into hard-to-reach organs and tumors), with cutting-edge cell and mRNA therapies. The team, composed of global scientists, innovators, and visionaries, is dedicated to shaping the future of targeted medicine through innovative and reliable clinical data, with the goal of making targeted medicine a reality for many.